Firehawk在冠状动脉介入治疗中的安全性和有效性分析

Effect Analysis of Firehawk on the Changes of Blood Vessel and Stent in Coronary Heart Disease

目的探讨国产靶向洗脱支架火鹰(Fierhawk)在冠状动脉介入治疗中的安全性和有效性。方法选取2016年1月至2017年6月在我院治疗的冠状动脉粥样硬化性心脏病患者83例,根据选取的支架分为Fierhawk组(n=44)和普通支架组(n=39),观察两组治疗前后狭窄程度及支架情况,同时行血管内超声(IVUS)评估血管情况,随访两组主要不良心脏事件发生情况。结果 Firehawk组随访结束时病变血管狭窄程度为(8.48±3.21)%,明显低于普通支架组,差异有统计学意义(P<0.05);Firehawk组和普通支架组支架直径、长度及个数比较差异无统计学意义(P>0.05);Firehawk组和普通支架组术后和随访结束时斑块+中膜横截面积和支架位置处外弹力膜横截面积比较差异无统计学意义(P>0.05);Firehawk组靶病变血运重建和支架内再狭窄发生率为2.30%和2.30%,明显低于普通支架组,差异有统计学意义(P<0.05)。结论 Firehawk在冠状动脉介入治疗中安全有效,值得临床推广使用。

Objective To evaluate the safety and efficacy of domestic target eluting stent （Fierhawk） in percutaneous coro- nary intervention. Methods 83 patients with coronary atherosclerotic heart disease treated in our hospital from January 2016 to June 2017 were selected, according to the selected stent, divided into Fierhawk group （n = 44）and ordinary stent group （n = 39 ）, the stenosis degree and stent condition of the two groups were observed before and after treatment, and the vessels were evaluated by intravascular ultrasound （ IVUS）, the major adverse cardiac events in two groups were followed up. Results At the end of follw up,the stenosis degree of vascular in Firehawk groupwas （ 8.48 ＋ 3.21 ） %, significantly lower than that of the ordinary stent group （ P 〈 0.05） ;There was no significant difference in diameter,length and number of stent between Firehawk group and ordinary stent group （P 〉 0. 05） ;There was no significant difference in laque ＋ middle membrane cross-sectional area and the cross-sectional area of the outer elastic membrane at the position of the stent between the Firehawk group and the ordinary stent group at the end of the operation and at the end of the follow-up period （ P 〉 0. 05 ） ; The incidence of target lesion revascularization and stent restenosis in Firehawk group were 2. 30% and 2. 30% ,which was significantly lower than that in the ordinary stent group （ P 〈 0. 05 ）. Conclusion Firehawk is safe and effective in percutaneous coronary intervention, and is worthy of clinical use.